GlaxoSmithKline (LON:GSK) received a GBX 2,000 ($26.13) price objective from equities researchers at HSBC in a note issued to investors on Thursday. The firm currently has a “buy” rating on the stock. HSBC’s price target suggests a potential upside of 32.68% from the company’s current price.
GSK has been the subject of several other reports. Barclays set a GBX 1,750 ($22.87) price target on shares of GlaxoSmithKline and gave the company a “buy” rating in a research note on Monday, July 23rd. Societe Generale set a GBX 1,000 ($13.07) price target on shares of GlaxoSmithKline and gave the company a “sell” rating in a research note on Monday, September 10th. UBS Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research note on Friday, October 26th. Shore Capital raised shares of GlaxoSmithKline from an “average” rating to a “buy” rating and set a GBX 41.74 ($0.55) price target for the company in a research note on Thursday, July 26th. Finally, Cfra set a GBX 1,550 ($20.25) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday, July 26th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of GBX 1,516.51 ($19.82).
GSK opened at GBX 1,507.40 ($19.70) on Thursday. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($16.14) and a 1-year high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: Marijuana Stocks
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.